evolcSign inStart free
Menu

Recordati Rare Diseases

Markets medicines for rare endocrine, oncology-hematology and metabolic diseases in around 150 countries

Puteaux, FranceFounded 1990recordatirarediseases.comWebsite technologies

+ Add to sales board

Highlights

  • New on EvolcAdded 2026-10-28

About Recordati Rare Diseases

Recordati Rare Diseases develops and markets medicines for rare and little-known diseases, including orphan and ultra-orphan conditions. Its core therapy areas are endocrinology, oncology-hematology and metabolic diseases. Its products include Carbaglu (carglumic acid) and Caphosol.

The company sells prescription medicines to patients, healthcare professionals and healthcare systems. It also develops clinical trials for orphan drugs and provides specialist regulatory affairs support, including orphan drug designations and marketing authorisation applications. The website describes the company as having a presence in around 150 countries.

Recordati Rare Diseases is part of the Recordati group, an international pharmaceutical group listed on the Italian Stock Exchange. The company was founded in 1990 and is headquartered in Puteaux, France. The group entered the rare diseases sector in 2007 with the acquisition of Orphan Europe.

Product: Prescription medicines for rare endocrine, oncology-hematology and metabolic diseases, such as Carbaglu and Caphosol.

Public tenders won

5 tenders won since 1 Jan 2024 from 5 public buyers in France, Portugal, worth €315k as awarded. From EU award notices (TED) that name Recordati Rare Diseases by its registry number.

  • 18 Mar 2026 CHU DE SAINT ETIENNE · Ght_MED_2025-019 FRA25_AC_Fourniture De Médicaments [2025-2027] notice
  • 7 Oct 2025 CHU de Clermont-Ferrand · Marché exclusif de fourniture d’un médicament en sus du GHS (FES) pour le GHT Territoires d’Auvergne Médicament : DINUTUXIMAB BETA 4.5 mg/ml (QARZIBA ®), solution à diluer pour perfusion notice
  • 8 May 2025 Unidade Local de Saúde do Alentejo Central, E. P. E. · Aquisição de Medicamentos de Consumo Geral da Farmácia · €91k notice
  • 8 Apr 2025 Unidade Local de Saúde Santa Maria, E.P.E. · 251G000432 - PASIREOTIDO 40 MG/ 2 ML SUSP INJ IM FR (várias dosagens) · €223k notice
  • 10 Feb 2025 Centre hospitalier universitaire de Caen Normandie · Fourniture de spécialité QARZIBA notice

Open tenders like these →

Jobs at Recordati Rare Diseases

No open positions listed right now.

Leadership

More biotech & pharma companies

  • Revobiom

    Microbial evolution technology for industrial and research teams developing functional microbial consortia
    Paris, FranceBiotech & pharmaFounded 2022
    Young companyNew on Evolc

  • Rime Bioinformatics

    Genomic analyses and custom bioinformatics tools for phage therapy, fermentation and microbiome R&D teams
    Palaiseau, FranceBiotech & pharmaFounded 2021
    New on Evolc

  • Roche

    Pharmaceutical drugs and diagnostic solutions for patients and healthcare professionals in France
    Boulogne-Billancourt, FranceBiotech & pharmaFounded 1980

  • Roowin

    Fine chemistry and cGMP drug-development services for pharmaceutical, biotechnology, and fine chemical companies
    Riom, FranceBiotech & pharmaFounded 19971 open job
    New on Evolc

  • Sanofi

    Biopharmaceutical company developing medicines and vaccines for patients, with France as its main R&D and industrial base
    Paris, FranceBiotech & pharmaFounded 1994
    New on Evolc

  • Santen

    Develops and supplies ophthalmic medicines and eye-care products for patients and healthcare professionals
    Puteaux, FranceBiotech & pharmaFounded 2000
    New on Evolc

All biotech & pharma companies →

Website technologies

Older, unverified list. Detection dates and supporting evidence are not yet available.

  • Apache
  • Drupal
  • Elementor
  • Matomo
  • WordPress
  • jQuery